Edwards Lifesciences Sees Q3 EPS $0.67 Vs $0.69 Est.; Sales $1.56B-$1.64B Vs $1.653B Est.
Portfolio Pulse from Benzinga Newsdesk
Edwards Lifesciences reported Q3 EPS of $0.67, missing the estimate of $0.69. Sales were between $1.56B and $1.64B, compared to the estimate of $1.653B.
July 24, 2024 | 8:18 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Edwards Lifesciences reported Q3 EPS of $0.67, missing the estimate of $0.69. Sales were between $1.56B and $1.64B, compared to the estimate of $1.653B.
The company's Q3 EPS and sales both missed analyst estimates, which is likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100